| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 145, 1291-1295, Copyright © 1994 by American Society for Investigative Pathology
REGULAR ARTICLES |
CR Boschman, S Stryker, JK Reddy and MS Rao
Department of Pathology, Northwestern University Medical School, Chicago, Illinois 60611.
To evaluate the incidence and stage at which p53 alterations occur in human pancreatic carcinogenesis, we examined primary and metastatic carcinomas, carcinoma in situ, and hyperplastic lesions with and without atypia for p53 protein overexpression by immunohistochemical procedure. Overexpression of p53 was observed in 40% (10/25) of primary tumors, 29% (2/7) of metastatic tumors, 36% (5/14) of carcinoma in situ, and 35% (6/17) of hyperplastic lesions. These results suggest that p53 protein overexpression is not only a common genetic alteration but also occurs very early in the development of these tumors. It is suggested that p53 overexpression can be used as a marker to identify precursor lesions that have increased potential to develop into malignant tumors.
This article has been cited by other articles:
![]() |
M. Pasca di Magliano, S. Sekine, A. Ermilov, J. Ferris, A. A. Dlugosz, and M. Hebrok Hedgehog/Ras interactions regulate early stages of pancreatic cancer. Genes & Dev., November 15, 2006; 20(22): 3161 - 3173. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. F. Hezel, A. C. Kimmelman, B. Z. Stanger, N. Bardeesy, and R. A. DePinho Genetics and biology of pancreatic ductal adenocarcinoma. Genes & Dev., May 15, 2006; 20(10): 1218 - 1249. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Bardeesy, A. J. Aguirre, G. C. Chu, K.-h. Cheng, L. V. Lopez, A. F. Hezel, B. Feng, C. Brennan, R. Weissleder, U. Mahmood, et al. From the Cover: Both p16Ink4a and the p19Arf-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse PNAS, April 11, 2006; 103(15): 5947 - 5952. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Dowen, T. Crnogorac-Jurcevic, R. Gangeswaran, M. Hansen, J. J. Eloranta, V. Bhakta, T. A. Brentnall, J. Luttges, G. Kloppel, and N. R. Lemoine Expression of S100P and Its Novel Binding Partner S100PBPR in Early Pancreatic Cancer Am. J. Pathol., January 1, 2005; 166(1): 81 - 92. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Khalid, R Pal, E Sasatomi, P Swalsky, A Slivka, D Whitcomb, and S Finkelstein Use of microsatellite marker loss of heterozygosity in accurate diagnosis of pancreaticobiliary malignancy from brush cytology samples Gut, December 1, 2004; 53(12): 1860 - 1865. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. V. Biankin, J. G. Kench, A. L. Morey, C.-S. Lee, S. A. Biankin, D. R. Head, T. B. Hugh, S. M. Henshall, and R. L. Sutherland Overexpression of p21WAF1/CIP1 is an Early Event in the Development of Pancreatic Intraepithelial Neoplasia Cancer Res., December 1, 2001; 61(24): 8830 - 8837. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Luttges, H. Galehdari, V. Brocker, I. Schwarte-Waldhoff, D. Henne-Bruns, G. Kloppel, W. Schmiegel, and S. A. Hahn Allelic Loss Is Often the First Hit in the Biallelic Inactivation of the p53 and DPC4 Genes During Pancreatic Carcinogenesis Am. J. Pathol., May 1, 2001; 158(5): 1677 - 1683. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Heinmoller, W. Dietmaier, H. Zirngibl, P. Heinmoller, W. Scaringe, K.-W. Jauch, F. Hofstadter, and J. Ruschoff Molecular Analysis of Microdissected Tumors and Preneoplastic Intraductal Lesions in Pancreatic Carcinoma Am. J. Pathol., July 1, 2000; 157(1): 83 - 92. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |